Related Experiment Video
Updated: Jun 21, 2025
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Direct-Acting Antiviral Treatment for Acute Hepatitis C in Japanese Patients: Clinical Course and Outcomes
Hiroshi Okano1, Katsumi Mukai1, Akira Nishimura1
1Gastroenterology, Suzuka General Hospital, Suzuka, JPN.
Insights
This study found that acute hepatitis C virus (HCV) infection cases were younger and had more severe hepatitis than chronic cases. Direct-acting antiviral (DAA) treatment showed similar effectiveness for both acute and chronic HCV infections.
Area of Science:
- Hepatology
- Infectious Diseases
- Virology
Background:
- Hepatitis C virus (HCV) infection poses a significant global health challenge.
- Distinguishing acute from chronic HCV infection is crucial for effective management.
- Limited data exists on the clinical characteristics and treatment outcomes of acute HCV in Japan.
Purpose of the Study:
- To analyze the clinical features of acute HCV infection.
- To compare outcomes of acute HCV infection with chronic HCV and other acute liver injuries.
- To evaluate the efficacy of direct-acting antiviral (DAA) treatment in acute HCV infection.
Main Methods:
- Retrospective analysis of 6 acute HCV cases diagnosed between October 2003 and December 2022.
- Comparison of demographic, clinical, and laboratory data with 402 chronic HCV cases and 636 acute liver injury cases.
- Assessment of DAA treatment effectiveness in acute and chronic HCV patients.
Main Results:
- Acute HCV patients were younger with more severe hepatitis and higher bilirubinemia than chronic HCV patients.
- Two acute HCV cases cleared spontaneously; four progressed to chronic infection requiring DAA treatment.
- DAA treatment efficacy was comparable between acute (75%) and chronic (90%) HCV infections (p=0.34).
Conclusions:
- Acute HCV infection presents distinct clinical features compared to chronic infection.
- DAA therapy is effective for both acute and chronic HCV infections, suggesting early treatment may prevent chronicity.
- Immediate DAA initiation for acute HCV is recommended, potentially interrupting transmission in high-risk groups.
Abstract:
We diagnosed six cases of acute hepatitis C virus (HCV) infection at our hospital between October 2003 and December 2022. During the same period, we diagnosed 402 cases of chronic HCV infection and 636 cases of acute hepatic injury. Acute HCV infection cases accounted for 1.4% of all HCV infections and 0.9% of all acute hepatic injury cases. The acute HCV infection group was younger, had more severe hepatitis, and exhibited higher levels of bilirubinemia compared to the chronic HCV infection group. Two acute HCV infection cases achieved spontaneous viral clearance, while the remaining four cases progressed to chronic infection and were treated with direct-acting antivirals (DAAs). Liver enzyme elevation and liver function deterioration did not differ significantly between the acute HCV and other acute liver injury groups. Notably, DAA treatment was equally effective for acute and chronic HCV cases (75% vs. 90%, p = 0.34). Early DAA treatment in acute cases might contribute to interrupting viral transmission among high-risk populations, such as people who inject drugs or men who have sex with men. While there are currently no specific guidelines for acute HCV infection treatment in Japan, our findings suggest that DAA therapy should be initiated immediately following diagnosis. Further studies with larger patient cohorts are warranted to confirm these observations.
